• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Overview of Technical and Cost Considerations in Complex Percutaneous Coronary Intervention.复杂经皮冠状动脉介入治疗的技术与成本考量概述
Interv Cardiol. 2014 Mar;9(1):17-22. doi: 10.15420/icr.2011.9.1.17.
2
Long-term clinical outcomes after percutaneous coronary intervention for ostial/mid-shaft lesions versus distal bifurcation lesions in unprotected left main coronary artery: the DELTA Registry (drug-eluting stent for left main coronary artery disease): a multicenter registry evaluating percutaneous coronary intervention versus coronary artery bypass grafting for left main treatment.经皮冠状动脉介入治疗开口/中段病变与无保护左主干冠状动脉分叉病变的长期临床结局:DELTA 注册研究(左主干冠状动脉疾病药物洗脱支架):一项多中心注册研究,评估经皮冠状动脉介入治疗与冠状动脉旁路移植术治疗左主干的疗效。
JACC Cardiovasc Interv. 2013 Dec;6(12):1242-9. doi: 10.1016/j.jcin.2013.08.005.
3
[Comparison on the long-term outcomes post percutaneous coronary intervention or coronary artery bypass grafting for bifurcation lesions in unprotected left main coronary artery].[经皮冠状动脉介入治疗或冠状动脉旁路移植术治疗无保护左主干冠状动脉分叉病变的长期预后比较]
Zhonghua Xin Xue Guan Bing Za Zhi. 2017 Jan 25;45(1):19-25. doi: 10.3760/cma.j.issn.0253-3758.2017.01.005.
4
Intravascular ultrasound to guide percutaneous coronary interventions: an evidence-based analysis.血管内超声引导经皮冠状动脉介入治疗:一项基于证据的分析。
Ont Health Technol Assess Ser. 2006;6(12):1-97. Epub 2006 Apr 1.
5
Impact of coronary anatomy and stenting technique on long-term outcome after drug-eluting stent implantation for unprotected left main coronary artery disease.药物洗脱支架置入治疗无保护左主干冠状动脉疾病后,冠状动脉解剖结构和支架技术对长期预后的影响。
JACC Cardiovasc Interv. 2014 Jan;7(1):29-36. doi: 10.1016/j.jcin.2013.08.013. Epub 2013 Dec 11.
6
Cost-effectiveness of percutaneous coronary intervention with drug-eluting stents versus bypass surgery for patients with 3-vessel or left main coronary artery disease: final results from the Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery (SYNTAX) trial.药物洗脱支架经皮冠状动脉介入治疗与旁路手术治疗 3 支血管病变或左主干病变患者的成本效益:紫杉醇药物洗脱支架与心脏手术(SYNTAX)试验的最终结果。
Circulation. 2014 Sep 30;130(14):1146-57. doi: 10.1161/CIRCULATIONAHA.114.009985. Epub 2014 Aug 1.
7
Percutaneous coronary intervention of unprotected left main coronary artery disease: procedural strategies and technical considerations.经皮冠状动脉介入治疗无保护左主干冠状动脉疾病:手术策略和技术考虑。
Catheter Cardiovasc Interv. 2012 Apr 1;79(5):812-22. doi: 10.1002/ccd.23042. Epub 2011 Jul 25.
8
Multivessel percutaneous coronary intervention: a new paradigm for a new century.多支血管经皮冠状动脉介入治疗:新世纪的新范例。
Minerva Cardioangiol. 2005 Oct;53(5):361-77.
9
Complex PCI procedures: challenges for the interventional cardiologist.复杂 PCI 手术:介入心脏病学家面临的挑战。
Clin Res Cardiol. 2018 Aug;107(Suppl 2):64-73. doi: 10.1007/s00392-018-1316-1. Epub 2018 Jul 5.
10
Percutaneous Coronary Intervention for Left Main Coronary Artery Bifurcation Lesions: Two-stent versus one-stent Strategy for Comparison of 6-month MACE.经皮冠状动脉介入治疗左主干冠状动脉分叉病变:双支架与单支架策略比较6个月主要不良心血管事件
J Coll Physicians Surg Pak. 2020 Sep;30(9):894-899. doi: 10.29271/jcpsp.2020.09.894.

引用本文的文献

1
Guiding Principles for the Clinical Use and Selection of Microcatheters in Complex Coronary Interventions.复杂冠状动脉介入治疗中微导管临床应用与选择的指导原则
Front Cardiovasc Med. 2022 Mar 9;9:724608. doi: 10.3389/fcvm.2022.724608. eCollection 2022.
2
Debate of Percutaneous Coronary Intervention versus Coronary Artery Bypass Grafting in a Multimorbidity Patient with Complex Coronary Lesions.复杂冠状动脉病变的多病患者行经皮冠状动脉介入治疗与冠状动脉旁路移植术的争论
Case Rep Cardiol. 2020 May 18;2020:9493519. doi: 10.1155/2020/9493519. eCollection 2020.

本文引用的文献

1
Cost-effectiveness of percutaneous coronary intervention in patients with stable coronary artery disease and abnormal fractional flow reserve.稳定型冠状动脉疾病伴异常血流储备分数患者行经皮冠状动脉介入治疗的成本效益。
Circulation. 2013 Sep 17;128(12):1335-40. doi: 10.1161/CIRCULATIONAHA.113.003059. Epub 2013 Aug 14.
2
Percutaneous coronary intervention, a historical perspective looking to the future.经皮冠状动脉介入治疗:展望未来的历史视角
J Thorac Dis. 2013 Jun;5(3):367-70. doi: 10.3978/j.issn.2072-1439.2013.04.21.
3
Late thrombosis after double versus single drug-eluting stent in the treatment of coronary bifurcations: a meta-analysis of randomized and observational Studies.双药洗脱支架与单药洗脱支架治疗冠状动脉分叉病变后迟发性血栓形成的Meta 分析:随机和观察性研究。
JACC Cardiovasc Interv. 2013 Jul;6(7):687-95. doi: 10.1016/j.jcin.2013.03.012. Epub 2013 Jun 14.
4
Cost-effectiveness of percutaneous coronary intervention with drug eluting stents versus bypass surgery for patients with diabetes mellitus and multivessel coronary artery disease: results from the FREEDOM trial.经皮冠状动脉介入治疗与旁路手术治疗糖尿病合并多支血管病变患者的成本效益比较:来自 FREEDOM 试验的结果。
Circulation. 2013 Feb 19;127(7):820-31. doi: 10.1161/CIRCULATIONAHA.112.147488. Epub 2012 Dec 31.
5
Association of public reporting for percutaneous coronary intervention with utilization and outcomes among Medicare beneficiaries with acute myocardial infarction.经皮冠状动脉介入治疗的公共报告与医疗保险受益人的急性心肌梗死患者的利用和结局的关联。
JAMA. 2012 Oct 10;308(14):1460-8. doi: 10.1001/jama.2012.12922.
6
Establishing the cost-effectiveness of percutaneous coronary intervention for chronic total occlusion in stable angina: a decision-analytic model.稳定型心绞痛患者慢性完全闭塞经皮冠状动脉介入治疗的成本效果分析:决策分析模型。
Heart. 2012 Dec;98(24):1790-7. doi: 10.1136/heartjnl-2012-302581. Epub 2012 Oct 4.
7
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.临界血流储备分数指导下的经皮冠状动脉介入治疗与稳定型冠心病的药物治疗。
N Engl J Med. 2012 Sep 13;367(11):991-1001. doi: 10.1056/NEJMoa1205361. Epub 2012 Aug 27.
8
A percutaneous treatment algorithm for crossing coronary chronic total occlusions.经皮冠状动脉慢性完全闭塞病变的治疗策略
JACC Cardiovasc Interv. 2012 Apr;5(4):367-79. doi: 10.1016/j.jcin.2012.02.006.
9
Functional assessment of jailed side branches in coronary bifurcation lesions using fractional flow reserve.使用血流储备分数评估冠状动脉分叉病变中闭塞边支的功能。
JACC Cardiovasc Interv. 2012 Feb;5(2):155-61. doi: 10.1016/j.jcin.2011.10.015.
10
Incidence and predictors of coronary stent thrombosis: evidence from an international collaborative meta-analysis including 30 studies, 221,066 patients, and 4276 thromboses.冠状动脉支架血栓形成的发生率和预测因素:来自包括 30 项研究、221066 名患者和 4276 例血栓形成的国际合作荟萃分析的证据。
Int J Cardiol. 2013 Jul 31;167(2):575-84. doi: 10.1016/j.ijcard.2012.01.080. Epub 2012 Feb 22.

复杂经皮冠状动脉介入治疗的技术与成本考量概述

Overview of Technical and Cost Considerations in Complex Percutaneous Coronary Intervention.

作者信息

Estrada J Raider, Paul Jonathan D, Shah Atman P, Nathan Sandeep

机构信息

University of Chicago Medicine, Section of Cardiology, Chicago, Illinois, US.

出版信息

Interv Cardiol. 2014 Mar;9(1):17-22. doi: 10.15420/icr.2011.9.1.17.

DOI:10.15420/icr.2011.9.1.17
PMID:29588772
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5808630/
Abstract

Complex percutaneous coronary intervention (PCI), encompassing an ever-expanding range of challenging lesion sets and patient populations, accounts for a significant proportion of PCI procedures being performed currently. Specific lesion types associated with lower rates of procedural success and higher rates of recurrence or major adverse cardiac events (MACE) include multivessel disease, unprotected left main coronary artery disease, fibrocalcific or undilatable lesions, chronic total occlusions, degenerated saphenous vein graft lesions, thrombotic lesions, and bifurcation disease. Validated tools and technical strategies currently exist to address most procedural scenarios encountered and should be familiar to the complex PCI operator. Anticipated clinical outcomes, projected resource utilization, and cost considerations should all factor into the decisions of when, how, and in whom to intervene.

摘要

复杂经皮冠状动脉介入治疗(PCI)涵盖了范围不断扩大的具有挑战性的病变类型和患者群体,在目前正在进行的PCI手术中占很大比例。与手术成功率较低、复发率或主要不良心脏事件(MACE)较高相关的特定病变类型包括多支血管病变、无保护左主干冠状动脉病变、纤维钙化或不可扩张病变、慢性完全闭塞病变、退化的大隐静脉桥血管病变、血栓性病变和分叉病变。目前已有经过验证的工具和技术策略来应对大多数遇到的手术情况,复杂PCI手术操作者应熟悉这些策略。预期的临床结果、预计的资源利用情况和成本考量都应纳入何时、如何以及对谁进行干预的决策因素。